Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Abbott has agreed to acquire cancer test-maker Exact ...

Your website’s domain name is the digital real estate your entire brand is built upon. Great domains are easy to remember, type in and share. With thousands of domain extensions and more than 332 ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

Exact Sciences stock crumbled Thursday — extending its losses this week — on its growing rivalry with Guardant Health and ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...